Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
暂无分享,去创建一个
[1] D. Hosmer,et al. Applied Logistic Regression , 1991 .
[2] W. Catalona,et al. Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.
[3] O. Nilsson,et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.
[4] A. Pantuck,et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.
[5] M. Brawer,et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. , 1995, Urology.
[6] W. Catalona,et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.
[7] W. Catalona,et al. Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml. , 1993, The Journal of urology.
[8] J. Moul,et al. Age-specific reference ranges for serum prostate-specific antigen in black men. , 1996, The New England journal of medicine.
[9] W. Catalona,et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.
[10] B. G. Blijenberg,et al. The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. , 1995, Urology.
[11] W. Catalona,et al. Racial differences in a prostate cancer screening study. , 1996, The Journal of urology.
[12] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[13] W. Catalona,et al. The nature of prostate cancer detected through prostate specific antigen based screening. , 1994, The Journal of urology.
[14] O. Nilsson,et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.
[15] P. Knekt,et al. Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.
[16] M. Terris,et al. Determination of prostate volume by transrectal ultrasound. , 1991, The Journal of urology.
[17] M. Stampfer,et al. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.
[18] P. Wingo,et al. Cancer statistics for African Americans, 1996 , 1996, CA: a cancer journal for clinicians.
[19] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[20] U. Stenman,et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.
[21] C G Chute,et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. , 1995, JAMA.